Expert Outlook: Arcutis Biotherapeutics Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
Arcutis Biotherapeutics (NASDAQ:ARQT) has received mixed ratings from 7 analysts in the past three months, with an average 12-month price target of $7.43, a significant decrease from the prior average. The company has shown impressive revenue growth of 5156.41% as of September 30, 2023, but faces challenges with a high debt-to-equity ratio and below-average ROE and ROA. Arcutis is developing dermatological treatments, with its lead product candidate ZORYVE completing Phase 3 trials.
January 03, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcutis Biotherapeutics has received a mix of analyst ratings with a lowered average price target of $7.43. The company's strong revenue growth contrasts with financial challenges such as a high debt ratio and below-average ROE/ROA.
The mixed analyst ratings and lowered price target suggest uncertainty, which could lead to short-term price volatility. However, the impressive revenue growth could counterbalance the negative aspects, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100